KYMERA THERAPEUTICS, INC. Net Income (Loss) Available to Common Stockholders, Basic
KYMERA THERAPEUTICS, INC. (KYMR) reported Net Income (Loss) Available to Common Stockholders, Basic of -$61.21 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2026-08-05
- KYMERA THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2026-06-30 was -$61.21M.
- KYMERA THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2026-03-31 was -$69.23M.
- KYMERA THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2025-12-31 was -$86.98M.
- KYMERA THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2025-09-30 was -$82.17M.
- KYMERA THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for fiscal 2025 was -$311.35M.
- KYMERA THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for fiscal 2024 was -$223.86M.
- KYMERA THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for fiscal 2023 was -$146.96M.
- KYMERA THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for fiscal 2022 was -$154.81M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$61.21M 10-Q · filed 2026-08-05 | -$130.44M 10-Q · filed 2026-08-05 | -$217.43M derived: sum of 3 quarters · filed 2026-08-05 | -$299.60M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$69.23M 10-Q · filed 2026-04-30 | -$156.22M derived: sum of 2 quarters · filed 2026-04-30 | -$238.39M derived: sum of 3 quarters · filed 2026-04-30 | -$315.00M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$86.98M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$169.16M derived: sum of 2 quarters · filed 2026-02-26 | -$245.77M derived: sum of 3 quarters · filed 2026-08-05 | -$311.35M 10-K · filed 2026-02-26 |
| 2025-09-30 | -$82.17M 10-Q · filed 2025-11-04 | -$158.79M derived: sum of 2 quarters · filed 2026-08-05 | -$224.37M 10-Q · filed 2025-11-04 | -$295.12M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$76.61M 10-Q · filed 2026-08-05 | -$142.19M 10-Q · filed 2026-08-05 | -$212.95M derived: sum of 3 quarters · filed 2026-08-05 | -$275.43M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$65.58M 10-Q · filed 2026-04-30 | -$136.33M derived: sum of 2 quarters · filed 2026-04-30 | -$198.82M derived: sum of 3 quarters · filed 2026-04-30 | -$240.88M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | -$70.75M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$133.24M derived: sum of 2 quarters · filed 2026-02-26 | -$175.30M derived: sum of 3 quarters · filed 2026-02-26 | -$223.86M 10-K · filed 2026-02-26 |
| 2024-09-30 | -$62.49M 10-Q · filed 2025-11-04 | -$104.55M derived: sum of 2 quarters · filed 2025-11-04 | -$153.11M 10-Q · filed 2025-11-04 | -$167.47M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | -$42.06M 10-Q · filed 2025-08-11 | -$90.62M 10-Q · filed 2025-08-11 | -$104.99M derived: sum of 3 quarters · filed 2026-02-26 | -$157.85M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | -$48.56M 10-Q · filed 2025-05-09 | -$62.92M derived: sum of 2 quarters · filed 2026-02-26 | -$115.79M derived: sum of 3 quarters · filed 2026-02-26 | -$154.59M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | -$14.37M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$67.23M derived: sum of 2 quarters · filed 2026-02-26 | -$106.03M derived: sum of 3 quarters · filed 2026-02-26 | -$146.96M 10-K · filed 2026-02-26 |
| 2023-09-30 | -$52.87M 10-Q · filed 2024-10-31 | -$91.67M derived: sum of 2 quarters · filed 2024-10-31 | -$132.59M 10-Q · filed 2024-10-31 | -$167.46M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | -$38.80M 10-Q · filed 2024-08-07 | -$79.73M 10-Q · filed 2024-08-07 | -$114.59M derived: sum of 3 quarters · filed 2025-02-27 | -$157.59M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | -$40.93M 10-Q · filed 2024-05-02 | -$75.79M derived: sum of 2 quarters · filed 2025-02-27 | -$118.80M derived: sum of 3 quarters · filed 2025-02-27 | -$159.05M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | -$34.87M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$77.87M derived: sum of 2 quarters · filed 2025-02-27 | -$118.12M derived: sum of 3 quarters · filed 2025-02-27 | -$154.81M 10-K · filed 2025-02-27 |
| 2022-09-30 | -$43.00M 10-Q · filed 2023-11-02 | -$83.26M derived: sum of 2 quarters · filed 2023-11-02 | -$119.94M 10-Q · filed 2023-11-02 | -$153.84M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | -$40.26M 10-Q · filed 2023-08-03 | -$76.94M 10-Q · filed 2023-08-03 | -$110.84M derived: sum of 3 quarters · filed 2024-02-22 | -$139.42M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | -$36.68M 10-Q · filed 2023-05-04 | -$70.58M derived: sum of 2 quarters · filed 2024-02-22 | -$99.17M derived: sum of 3 quarters · filed 2024-02-22 | -$123.83M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | -$33.90M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | -$62.48M derived: sum of 2 quarters · filed 2024-02-22 | -$87.14M derived: sum of 3 quarters · filed 2024-02-22 | -$100.22M 10-K · filed 2024-02-22 |
| 2021-09-30 | -$28.58M 10-Q · filed 2022-11-03 | -$53.24M derived: sum of 2 quarters · filed 2022-11-03 | -$66.32M 10-Q · filed 2022-11-03 | -$79.00M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | -$24.66M 10-Q · filed 2022-08-09 | -$37.73M 10-Q · filed 2022-08-09 | -$50.42M derived: sum of 3 quarters · filed 2023-02-23 | -$58.41M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | -$13.07M 10-Q · filed 2022-05-03 | -$25.76M derived: sum of 2 quarters · filed 2023-02-23 | -$33.75M derived: sum of 3 quarters · filed 2023-02-23 | -$47.73M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | -$12.69M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | -$20.67M derived: sum of 2 quarters · filed 2023-02-23 | -$34.66M derived: sum of 3 quarters · filed 2023-02-23 | -$54.64M 10-K · filed 2023-02-23 |
| 2020-09-30 | -$7.99M 10-Q · filed 2021-11-10 | -$21.98M derived: sum of 2 quarters · filed 2021-11-10 | -$41.96M 10-Q · filed 2021-11-10 | -$53.47M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | -$13.99M 10-Q · filed 2021-08-06 | -$33.97M 10-Q · filed 2021-08-06 | -$45.48M derived: sum of 3 quarters · filed 2022-02-24 | -$56.90M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | -$19.98M 10-Q · filed 2021-05-06 | -$31.50M derived: sum of 2 quarters · filed 2022-02-24 | -$42.91M derived: sum of 3 quarters · filed 2022-02-24 | |
| 2019-12-31 | -$11.51M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | -$22.93M derived: sum of 2 quarters · filed 2022-02-24 | -$41.25M 10-K · filed 2022-02-24 | |
| 2019-09-30 | -$11.42M 10-Q · filed 2020-11-05 | -$29.73M 10-Q · filed 2020-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |